🔗 Share this article US and UK Strike Zero-Tariff Agreement on Prescription Drugs. Conceptual image of drug trade. The United Kingdom and the United States have hammered out a significant bilateral deal that will keep zero import taxes on British pharmaceutical exports going into the US market. The Terms of the Deal As part of the deal, the UK has pledged to boost funding on pharmaceuticals through the public health system. This commitment secures that tariffs on these crucial goods will be held at zero for a timeframe of three years. This development follows earlier threats to hike tariffs on patented pharmaceutical imports, with figures discussed as high as 100%. "This deal with the UK strengthens the global environment for innovative medicines and brings much-needed balance to transatlantic pharmaceutical trade," an announcement noted. Commercial Impact Pharmaceuticals represent one of the Britain's biggest goods shipped to the United States, which is easily the primary market for large British pharmaceutical firms. Export figures indicate that in the year to the end of last September, the UK sold drugs valued at over eleven billion pounds to the US. This figure accounted for nearly one-fifth of British export trade in that span. "This deal secures work, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary stated. Detailed UK Commitments The pact entails several notable commitments from the UK: Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new treatments to be prohibitively costly by 25%. Higher Drug Budget: There is a target to increase total public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years. Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be restricted at 15%. In the past, repayments were more than 20%. Recent Tensions The deal follows a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and NHS adoption. This friction were heightened by claims that US customers were paying several times more for the same drugs than people in the UK and Europe. In recent months, several major drug company projects in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been directed toward projects in the United States. The Science Minister acknowledged that the NHS needed to spend more on treatments, noting that its spending on drugs had declined as a share of its resources over the past decade.
Conceptual image of drug trade. The United Kingdom and the United States have hammered out a significant bilateral deal that will keep zero import taxes on British pharmaceutical exports going into the US market. The Terms of the Deal As part of the deal, the UK has pledged to boost funding on pharmaceuticals through the public health system. This commitment secures that tariffs on these crucial goods will be held at zero for a timeframe of three years. This development follows earlier threats to hike tariffs on patented pharmaceutical imports, with figures discussed as high as 100%. "This deal with the UK strengthens the global environment for innovative medicines and brings much-needed balance to transatlantic pharmaceutical trade," an announcement noted. Commercial Impact Pharmaceuticals represent one of the Britain's biggest goods shipped to the United States, which is easily the primary market for large British pharmaceutical firms. Export figures indicate that in the year to the end of last September, the UK sold drugs valued at over eleven billion pounds to the US. This figure accounted for nearly one-fifth of British export trade in that span. "This deal secures work, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary stated. Detailed UK Commitments The pact entails several notable commitments from the UK: Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new treatments to be prohibitively costly by 25%. Higher Drug Budget: There is a target to increase total public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years. Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be restricted at 15%. In the past, repayments were more than 20%. Recent Tensions The deal follows a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and NHS adoption. This friction were heightened by claims that US customers were paying several times more for the same drugs than people in the UK and Europe. In recent months, several major drug company projects in the UK have been paused or scrapped, while multi-billion-dollar funding commitments have been directed toward projects in the United States. The Science Minister acknowledged that the NHS needed to spend more on treatments, noting that its spending on drugs had declined as a share of its resources over the past decade.